Still, the main factor defining their anti-PCa effects, relative to TMPRSS2-ERG-fusion positivity, appears to be the ability of the NSAIDs to significantly affect the proliferative growth phase of the fusion-positive tumors. The gene discussed is ERG; the disease is posterior cortical atrophy.